In what could be a big win for the pharmaceutical industry, legislation is close to being signed into law in New York State that would absolve drug makers from paying for so-called drug take-back programs.
Identical bills recently passed the state Senate and Assembly that would, instead, require chain pharmacies to cover the costs, a move that bucks a growing trend on the West Coast, where drug makers have increasingly been forced by local governments to pay for these programs.
About the Author Reprints
